


State-of-the-art Treatment of Coronary Heart Disease

**Medical therapy vs PCI/CABG
in stable CHD and ACS**



Prof. Dr. med. Dr. Frans Santosa, SpJP, FIHA

Internist, Cardiologist, Angiologist

UNI-MED

UNI-MED Verlag AG
Bremen - London - Boston

Contents

1.	From Primary to Secondary Prevention	31
1.1.	Definition	31
1.2.	Risk factors for atherosclerosis	31
1.3.	Aims of secondary prevention	33
1.4.	Primary vs secondary prevention	33
1.5.	Risk stratification	34
1.5.1.	The PROCAM score	34
1.5.2.	The ESC risk score	34
1.5.3.	The Framingham risk score	37
1.6.	Blood pressure/HbA _{1c} goals	37
1.7.	HbA _{1c} target in diabetics	39
1.8.	Lipids	39
1.8.1.	2004 NCEP (ATP III) guidelines	40
1.8.2.	ACC/AHA guidelines	40
1.8.3.	ESC and ESC/EA guidelines	40
1.8.4.	Conversion factor for lipids from mg/dl to mmol/l	41
1.9.	Non-pharmacological therapeutic measures	41
1.10.	Lifestyle and mortality risk	41
1.11.	Who has the highest cardiovascular risk?	42
1.12.	NSAIDs and cardiovascular risk	43
1.13.	Vitamin D and atherosclerosis	43
1.14.	Exposure to ambient air pollution and noise	43
1.14.1.	Ambient air pollution	43
1.14.2.	Environmental noise exposure	44
1.15.	MI risk with testosterone and PDE 5 inhibitors	44
1.16.	Cardiovascular risk and events in low, middle and high income countries	44
1.17.	Summary	44
1.18.	References	44
2.	Manifestations and Prognosis of CAD	48
2.1.	Manifestations of atherosclerosis	48
2.2.	Manifestations of CAD	48
2.2.1.	Classification of stable a.p.	49
2.2.2.	Acute coronary syndrome	49
2.3.	Prognosis of CAD	50
2.3.1.	Predictors of prognosis	50
2.3.2.	Prognosis and LV function	50
2.3.3.	Prognosis and LVEF	50
2.3.4.	Prognosis and coronary findings	50
2.3.5.	Prognosis and nonobstructive CAD	51
2.3.6.	Prognosis and heart rate	51
2.3.6.1.	Heart rate in chronic CAD with left ventricular dysfunction	51
2.3.6.2.	Discharge heart rate after myocardial infarction	51
2.3.7.	Prognosis depending on risk factors	52
2.4.	Prognosis and gender	52

2.5.	Prognosis in renal insufficiency	52
2.6.	Prognosis and diabetes	53
2.7.	Prognosis and type of medical care	54
2.8.	Prognosis for myocardial infarction	54
2.8.1.	Prognosis during / after myocardial infarction	54
2.8.2.	Prognosis after STEMI vs NSTEMI	54
2.8.3.	Prognosis after ACS	55
2.8.4.	Acute MI and time of admission to hospital	55
2.9.	An obesity paradox in ACS?	55
2.10.	Decrease in CAD mortality?	55
2.11.	Prognosis with guideline-oriented therapy?	57
2.12.	National differences in prognosis for AMI	57
2.13.	Refractory a.p. – Prognosis?	57
2.14.	A.p. without CHD?	58
2.15.	Cardiac syndrome X	58
2.16.	Prognosis in ACS and AV III or Mobitz II	58
2.17.	Radial vs femoral access in ACS – The MATRIX study	58
2.18.	Summary	59
2.19.	References	59

3.	From the Endothelial Defect to Myocardial Infarction	62
3.1.	The importance of the endothelium	62
3.2.	The acetylcholine test as a method to demonstrate endothelial dysfunction	63
3.3.	Clinical impact of endothelial dysfunction during stress	63
3.4.	Endothelial dysfunction as a prognostic indicator	64
3.5.	Endothelial progenitor cells	64
3.6.	Atherosclerosis in the coronary region	65
3.6.1.	From fatty streak to plaque	65
3.6.2.	The unstable plaque	65
3.6.3.	What types of stenosis result in most infarctions?	66
3.6.4.	Remodelling of vessels	66
3.6.5.	Restenosis after intervention	67
3.7.	From atherothrombosis to the acute syndrome	67
3.8.	Histomorphology of vulnerable plaques	68
3.9.	Remodelling of the left ventricle after myocardial infarction	68
3.10.	Collateral formation in atherosclerosis	69
3.11.	The natural course of atherosclerosis	70
3.12.	Summary	70
3.13.	References	71

4.	Pathophysiology of CAD and Strategies for Secondary Prevention	73
4.1.	Coronary insufficiency	73
4.2.	Determinants of the myocardial O ₂ requirement	74
4.3.	Heart rate	74
4.3.1.	Heart rate and duration of diastole	74
4.3.2.	Heart rate in CHD and collaterals	75
4.3.2.1.	Situation with normal heart rate	75

4.3.2.2.	Situation with increased heart rate	75
4.4.	Antianginal agents and their points of attack	75
4.4.1.	Previous antianginal agents	75
4.4.2.	Ivabradine, the first I ₁ channel inhibitor	75
4.4.3.	Ranolazine	76
4.5.	Strategies for secondary prevention	76
4.6.	Therapeutic priorities depending on the form of presentation of CAD	77
4.6.1.	Chronic stable CAD / post-infarction status	77
4.6.2.	Unstable angina pectoris / NSTEMI	77
4.6.3.	Acute myocardial infarction (STEMI)	77
4.6.4.	After CABG and PTCA (PCI)	77
4.6.5.	CAD patients with ventricular arrhythmias	78
4.6.6.	CAD with LV systolic dysfunction	78
4.7.	Stem cell therapy	78
4.8.	Myocardial infarction due to embolism	78
4.9.	Summary	78
4.10.	References	79

5.	Nitrates and Other Antianginal Agents	81
5.1.	Mechanism of action of nitrates	81
5.2.	Nitrate drugs	81
5.3.	Do nitrates prolong survival in CAD?	82
5.3.1.	The ISIS-4 study	82
5.3.2.	The GISSI-3 study	82
5.3.3.	The meta-analysis in ISIS-4	83
5.4.	Nitrates in secondary prevention	83
5.5.	Molsidomine	83
5.5.1.	The ESPRIMO study	83
5.5.2.	The ACCORD study	83
5.6.	Trapidil	84
5.6.1.	The STARC study	84
5.7.	Nicorandil, a potassium channel opener	84
5.7.1.	The IONA study	84
5.8.	Ranolazine	85
5.8.1.	The CARISA study	85
5.8.2.	The MERLIN-TIMI-36 study in ACS	85
5.8.3.	The RIVER-PCI study	86
5.9.	Trimetazidine	86
5.10.	Guidelines for anti-anginal drugs	86
5.10.1.	ESC guidelines for stable CHD	86
5.10.2.	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guidelines for stable CHD	86
5.10.3.	2014 AHA/ACC NSTEMI-ACS guidelines	87
5.11.	Summary	87
5.12.	References	87

6.	Beta-Blockers	90
6.1.	Mechanism of action of beta-blockers	90
6.2.	Classification of beta-blockers	90

6.3.	Differences between beta-blockers	90
6.4.	Treatment aims on beta-blockers	91
6.5.	Beta-blockers in post-infarct patients	91
6.5.1.	The Norwegian Timolol Study	91
6.5.2.	Beta-blocker Heart Attack Trial (BHAT)	91
6.5.3.	The metoprolol meta-analysis	92
6.5.4.	Beta-blockers in the meta-analysis by Yusuf	92
6.6.	Who benefits most?	92
6.6.1.	Patients with compensated heart failure	92
6.6.2.	Patients with reduced ejection fraction	93
6.6.3.	Older patients benefit more from beta-blockers	93
6.6.4.	Diabetics and beta-blockers	93
6.6.5.	Beta-blockers in COPD patients?	93
6.7.	Do all beta-blockers have a secondary prevention effect?	94
6.8.	Can beta-blockers be used for secondary prevention in CAD without infarction?	94
6.8.1.	Beta-blocker studies in CAD without infarction	94
6.8.2.	Prognosis of myocardial infarction on beta-blockers	94
6.8.3.	Beta-blockers in chronic CHD?	95
6.8.3.1.	The REACH Register	95
6.8.3.2.	The post-analysis of the CHARISMA study	95
6.8.4.	Beta-blockers in newly diagnosed CHD	95
6.8.5.	Beta-blockers after CABG	96
6.9.	Beta-blockers in heart failure	96
6.10.	Third-generation beta-blockers	96
6.11.	Beta-blockers in LV dysfunction after infarction – The CAPRICORN study	96
6.12.	Guidelines	98
6.12.1.	2011, 2012, 2013 AHA/ACCF guidelines	98
6.12.2.	2014 AHA/ACC NSTE-ACS guidelines	98
6.12.3.	2008, 2011, 2012 ESC guidelines	98
6.13.	Summary	99
6.14.	References	100

7.	Calcium antagonists	103
7.1.	Mechanism of action of calcium antagonists	103
7.2.	Differences between the calcium antagonists	103
7.3.	Calcium antagonists in stable angina	103
7.4.	Dihydropyridines in postinfarct patients	104
7.5.	Diltiazem in postinfarct patients	104
7.5.1.	The diltiazem reinfarction study	104
7.5.2.	The MDPIT study	104
7.5.3.	The INTERCEPT study	105
7.6.	Verapamil in postinfarct patients	105
7.6.1.	The DAVIT II study	105
7.6.2.	DAVIT II study vs MDPIT study	105
7.6.3.	The CRIS study	106
7.7.	Hypertensive vs normotensive postinfarct patients	106
7.8.	Third-generation calcium antagonists in CAD	106
7.8.1.	Characteristics of third-generation calcium antagonists	106
7.8.2.	The PREVENT study with amlodipine in CAD	107

7.8.3.	The CAPARE5 study with amlodipine after PTCA	107
7.8.4.	The CAMELOT study	107
7.9.	AHA/ACCF and ESC guidelines	108
7.9.1.	AHA/ACCF guidelines	108
7.9.2.	ESC guidelines	108
7.10.	Summary	109
7.11.	References	109

8.	ACE Inhibitors	111
8.1.	Mechanism of action	111
8.2.	Pathophysiological basis of ACE inhibitor treatment	111
8.2.1.	Left ventricular remodelling	111
8.2.2.	Cardiac and systemic compensatory mechanisms after infarction	112
8.2.3.	Vascular effects of ACE inhibitors	112
8.3.	ACE inhibitors and aspirin	113
8.4.	Postinfarction studies with ACE inhibitors	114
8.4.1.	The SAVE study	115
8.4.2.	The AIRE study	115
8.4.3.	The TRACE study	116
8.4.4.	The meta-analysis of the ACE inhibitor studies in postinfarction patients	116
8.4.5.	Review of ACE inhibitor studies in and after MI	117
8.5.	ACE inhibitors and risk of AF	117
8.6.	The HOPE study	117
8.6.1.	Results in the overall population	117
8.6.2.	Results in diabetics (MICRO-HOPE)	118
8.6.3.	Effects of ramipril independent of a reduction in blood pressure	118
8.6.4.	Evaluation of the HOPE study	118
8.6.5.	ACE inhibitors and statins – HOPE subgroup analysis	119
8.7.	ACE inhibitors and rate of infarction	119
8.8.	ACE inhibitors in association with and after PTCA – The QUIET study	119
8.9.	ACE inhibitors in CAD patients with a lower risk	120
8.9.1.	The EUROPA study	120
8.9.2.	The PEACE study	120
8.9.3.	HOPE vs EUROPA vs PEACE	121
8.9.4.	The meta-analyses of ACE inhibitor studies with preserved LV function	121
8.10.	AHA/ACCF and ESC guidelines	122
8.10.1.	AHA/ACCF guidelines	122
8.10.2.	ESC guidelines	122
8.11.	Summary	123
8.12.	References	123

9.	AT₁ Receptor Blockers	126
9.1.	The mechanism of action	126
9.2.	AT ₁ receptor blockers and pleiotropic effects	126
9.3.	Clinical studies in CAD	127
9.3.1.	The OPTIMAAL study	127
9.3.2.	The VALIANT study	127
9.3.3.	The ONTARGET study	128
9.3.4.	The TRANSCEND study	129

9.3.5.	The PROFESS study.....	129
9.4.	Combination of ACE inhibitor plus AT ₁ receptor blocker.....	130
9.5.	ACC/AHA and ESC guidelines.....	130
9.5.1.	ACC/AHA.....	130
9.5.2.	ESC.....	131
9.6.	Summary.....	131
9.7.	References.....	131
10.	Statins and Non-Statins (Ezetimibe, PCSK9 Inhibitors)	133
10.1.	Situation before the statin era.....	133
10.2.	Mechanism of action of the statins.....	133
10.3.	A comparison of statins.....	133
10.3.1.	Pharmacological differences.....	133
10.3.2.	Statins and extent of LDL reduction.....	134
10.4.	Statins and dose-effect relationship.....	134
10.5.	Statins in secondary prevention – The evidence from studies.....	135
10.5.1.	The 4S study.....	135
10.5.2.	The CARE study.....	136
10.5.3.	The LIPID study.....	137
10.5.4.	A comparison of the 3 lipid studies.....	137
10.5.5.	The Heart Protection Study (HPS).....	138
10.6.	The time for using a statin during and after acute coronary syndrome.....	139
10.7.	Statins and number of revascularisations.....	140
10.8.	Statins after CABG and PTCA.....	140
10.8.1.	The Post-CABG study.....	140
10.8.2.	The CARE subgroup of revascularisation patients.....	140
10.8.3.	The FLARE study.....	141
10.9.	Statins in PTCA.....	141
10.9.1.	The study by Chan et al.....	141
10.9.2.	The LIPS study.....	142
10.10.	Statins before PCI?.....	142
10.11.	Who benefits from LDL lowering? Younger or older patients?.....	143
10.11.1.	The PROSPER study.....	143
10.12.	Additional effects of statins.....	143
10.12.1.	Plaque regression.....	143
10.12.2.	From an unstable plaque to a stable plaque.....	144
10.12.3.	The improvement in vasomotor function.....	145
10.12.4.	Anti-inflammatory effects.....	145
10.12.5.	Statins and change in the plaque.....	145
10.13.	The greater the LDL reduction, the better.....	146
10.13.1.	The AVERT study.....	146
10.13.2.	The REVERSAL study.....	146
10.13.3.	The ASTEROID study.....	147
10.13.4.	The PROVE-IT study.....	147
10.13.5.	The TNT study.....	148
10.13.6.	The IDEAL study.....	148
10.13.7.	PROVE-IT vs TNT vs IDEAL.....	149
10.13.8.	Intensive vs moderate statin therapy – A meta-analysis.....	149

10.13.9.	Efficacy and safety of more intensive lowering LDL cholesterol	149
10.13.9.1.	Intensive vs less intensive LDL reduction	149
10.13.9.2.	Statin vs placebo	149
10.13.9.3.	Both meta-analyses combined	150
10.13.10.	Should statins be used if the LDL is <60 mg/dl?	150
10.14.	Statins in high-risk patients	151
10.14.1.	The ASCOT-LLA study	151
10.14.2.	The CARDS study	152
10.15.	Two maximum statin doses – The SATURN trial	152
10.16.	Statins and diabetes risk	153
10.17.	Non-statins	153
10.17.1.	Ezetimibe in the IMPROVE-IT trial	153
10.17.2.	PCSK9 inhibitors	155
10.17.3.	CEPT inhibitors	156
10.18.	LDL treatment targets today – The guidelines	156
10.18.1.	NCEP (ATP III)	156
10.18.2.	2011, 2012, 2013 ACCF/AHA	157
10.18.3.	2013, 2014 and 2015 ADA	158
10.18.4.	2011, 2012 ESC and 2011 ESC/EAS	158
10.18.5.	ACC/AHA guidelines on cholesterol to reduce atherosclerotic cardiovascular risk in adults	159
10.18.6.	2014 AHA/ACC NSTE-ACS guidelines	159
10.18.7.	ACC/AHA focused update of secondary prevention lipid performance measures	159
10.19.	Summary	160
10.20.	References	161

11.	Antiplatelet Agents	166
11.1.	Antiplatelet agents – An overview	166
11.2.	Mechanism of action of antiplatelet agents	166
11.3.	Molecular target of the thienopyridines	167
11.4.	Prasugrel vs clopidogrel	167
11.4.1.	Bioactivation	167
11.4.1.1.	Clopidogrel	167
11.4.1.2.	Prasugrel	167
11.4.2.	Comparison of the effect of clopidogrel vs prasugrel	167
11.5.	Ticagrelor and cangrelor	168
11.6.	Clopidogrel vs prasugrel vs ticagrelor	168
11.7.	Glycoprotein IIb/IIIa receptor inhibitors	169
11.8.	Aspirin (acetylsalicylic acid)	169
11.8.1.	The meta-analysis of the APTs' Collaboration in postinfarct patients	169
11.8.2.	Aspirin after CABG and PTCA	169
11.8.3.	The SAPAT study – Aspirin in stable CAD	170
11.8.4.	The aspirin dosage	170
11.8.5.	On the optimal aspirin dose	171
11.8.5.1.	Aspirin dose after ACS – The CURE and PCI-CURE studies	171
11.9.	Aspirin plus low-dose coumarins	171
11.9.1.	The CAR5 study	171
11.9.2.	The CHAMP study	172
11.10.	Clopidogrel vs aspirin	172

11.11.	Clopidogrel plus aspirin.....	173
11.11.1.	Clopidogrel after stenting – The CLASSIC5 study	173
11.11.2.	Clopidogrel vs ticlopidine after stenting – Results of a meta-analysis.....	173
11.11.3.	How long after BMS should clopidogrel plus aspirin be given for?.....	173
11.11.4.	Clopidogrel plus aspirin with DES – how long?	174
11.11.4.1.	The effect of six months DAPT	174
11.11.4.2.	The effect DAPT for more than one year.....	176
11.11.5.	Clopidogrel plus aspirin after brachytherapy	177
11.11.6.	Aspirin plus clopidogrel after STEMI	177
11.11.7.	Aspirin plus clopidogrel during urgent intervention.....	178
11.11.8.	Clopidogrel reloading in the case of repeat PCI?.....	178
11.12.	Clopidogrel and interaction with PPIs	178
11.13.	Rebound phenomena and resistance.....	179
11.13.1.	An aspirin rebound phenomenon?	179
11.13.2.	Aspirin resistance	180
11.13.3.	A clopidogrel rebound phenomenon?	180
11.13.4.	Clopidogrel resistance?	180
11.14.	Measurement of platelet reactivity – A treatment advisor?	180
11.15.	Vorapaxar – The PAR-1 receptor antagonist.....	181
11.16.	Ticagrelor in secondary prevention – The PEGASUS-TIMI 54 study.....	182
11.17.	Duration of DAPT?.....	183
11.18.	Current guidelines.....	183
11.18.1.	AHA/ACC guidelines	183
11.18.2.	2010 and 2014 ESC/EACTS guidelines.....	184
11.18.3.	Combination of platelet aggregation inhibitors, 2013 and 2014 European guidelines.....	185
11.18.4.	2016 ACC/AHA Guideline Update on Duration of DAPT.....	185
11.19.	Summary.....	185
11.20.	References	186

12.	Anticoagulants	191
12.1.	The Sixty Plus study in the elderly	191
12.2.	The WARIS-1 study.....	191
12.3.	The ASPECT-1 study	191
12.4.	The ASPECT-2 study	192
12.5.	The WARIS-2 study.....	192
12.6.	The APRICOT-2 study	192
12.7.	Indications for coumarins today.....	192
12.8.	Antithrombotic treatment in AF.....	193
12.8.1.	Coumarins vs aspirin in AF.....	193
12.8.2.	Aspirin plus clopidogrel vs warfarin – The ACTIVE W study.....	193
12.8.3.	The ACTIVE A study	194
12.8.4.	Risk stratification in AF	194
12.8.5.	Triple therapy in AF	194
12.8.6.	Aspirin vs coumarins in AF.....	195
12.9.	A new era for anticoagulation in AF	195
12.9.1.	Dabigatran – The RE-LY study	196
12.9.2.	Rivaroxaban – The ROCKET-AF study	197
12.9.3.	Apixaban – The ARISTOTLE study	197
12.9.4.	Edoxaban – The ENGAGE AF-TIMI 48 study.....	198

12.9.5.	Comparison of end points in RE-LY, ROCKET AF, ARISTOTLE	199
12.9.6.	Meta-analysis of RE-LY, ROCKET AF and ARISTOTLE	199
12.9.7.	Meta-analysis of RE-LY, ROCKET AF, ARISTOTLE and ENGAGE AF	200
12.9.8.	Pharmacodynamics of NOACs	200
12.10.	Apixaban vs aspirin in AF – The AVERROES study	200
12.11.	Dabigatran in mechanical heart valves – The RE-ALIGN study	201
12.12.	Duration of triple therapy?	201
12.12.1.	The WOEST study	201
12.12.2.	The ISAR-Triple study	201
12.13.	VKA plus aggregation inhibitors in stable CAD and AF?	202
12.14.	Bridging in AF with LMWH – Yes or no?	202
12.15.	Current guidelines	203
12.15.1.	AHA/ACCF and American College of Chest Physicians	203
12.15.2.	2012 ESC guidelines for AF	203
12.15.3.	The ESC joint consensus document on dual and triple therapy in AF and ACS	203
12.15.4.	2014 AHA/ACC/HRS-AF guidelines	203
12.15.5.	2014 AHA/ASA guidelines after stroke/TIA	204
12.16.	Summary	204
12.17.	References	205

13. Antihypertensive Agents 208

13.1.	Hypertension and risk in CAD	208
13.2.	The HOPE study	208
13.2.1.	Subgroup analysis of the CAD patients in the HOT study	208
13.3.	Isolated systolic hypertension (ISH)	209
13.4.	The INVEST study	209
13.4.1.	The diabetics in the INVEST study	209
13.4.2.	The J curve in INVEST patients	210
13.5.	The VALUE study	210
13.6.	The EUROPA study	210
13.6.1.	Calcium antagonists plus ACE inhibitors in chronic stable CAD	211
13.7.	Which combination therapy – The ACCOMPLISH study	211
13.7.1.	CAD patients of the ACCOMPLISH study	212
13.8.	Blood pressure after ACS	213
13.9.	Effects of sodium reduction	213
13.10.	Target blood pressure values in CAD – The guidelines	213
13.10.1.	The ESC and ESH guidelines	213
13.10.2.	AHA and ACCF/AHA guidelines	214
13.10.3.	2015 AHA/ACC/ASH guidelines	215
13.10.4.	ADA guidelines	215
13.10.5.	AHA/ADA update 2015/2016	215
13.11.	Summary	215
13.12.	References	216

14. Omega-3 Fatty Acids 219

14.1.	The GISSI Prevention study	219
14.2.	The OMEGA study	220
14.3.	Conclusion	220

14.4.	Current guidelines	220
14.5.	Summary	221
14.6.	References	221
15.	Ivabradine, the I_c Channel Blocker	222
15.1.	Heart rate and risk in CAD	222
15.2.	Ivabradine and effects on symptoms	222
15.3.	Ivabradine and effects on prognosis	222
15.3.1.	The BEAUT(UL) study	222
15.3.1.1.	Subgroup analysis of BEAUT(UL) in limiting angina pectoris	223
15.3.2.	The SHiT study	224
15.3.3.	Ivabradine for stable CAD – The SIGNIFY study	224
15.4.	Indications for ivabradine (EMA 2015)	225
15.5.	Current guidelines	226
15.5.1.	ESC guidelines	226
15.5.2.	2012 ACCF/AHA et al. guidelines for stable CAD	226
15.6.	Summary	226
15.7.	References	227
16.	UA/NSTEMI = NSTEMI-ACS	229
16.1.	Definition	229
16.2.	Diagnosis of ACS (UA/NSTEMI/STEMI)	229
16.2.1.	Highly sensitive troponin tests	229
16.2.2.	Copeptin testing	231
16.3.	The prognosis in UA/NSTEMI	231
16.4.	Aims of treatment	232
16.5.	Nitrates in UA/NSTEMI	232
16.6.	Beta-blockers	232
16.7.	Calcium antagonists	232
16.7.1.	Meta-analysis by Held	232
16.7.2.	The HINT study	232
16.7.3.	The Diltiazem Reinfarction study	232
16.8.	Aspirin	233
16.9.	Heparin in unstable angina / NSTEMI	233
16.9.1.	Unfractionated heparin	233
16.9.2.	Low-molecular-weight heparin	233
16.9.2.1.	The ESSENCE study	233
16.9.2.2.	The TIMI 11B study	233
16.9.2.3.	The TIMI 11B ESSENCE meta-analysis	234
16.9.2.4.	The INTERACT study	234
16.9.2.5.	The SYNERGY study	234
16.9.2.6.	The A to Z study	234
16.10.	Pentasaccharides	234
16.10.1.	The OASIS-5 study	234
16.11.	Bivalirudin	234
16.12.	GP IIb/IIIa inhibitors in UA/NSTEMI	235
16.12.1.	The PRISM study	235
16.12.2.	The PRISM-PLUS study	235
16.12.3.	The PURSUIT study	235

16.12.4.	The meta-analysis of studies with GP IIb/IIIa inhibitors.....	236
16.12.5.	GP IIb/IIIa inhibitors – Diabetics vs non-diabetics.....	236
16.13.	Clopidogrel plus aspirin in UA/NSTEMI	237
16.13.1.	The CURE study.....	237
16.13.2.	The PCI-CURE results.....	238
16.13.3.	Benefit of clopidogrel in relation to risk.....	239
16.13.4.	The ARMYDA-2 study.....	239
16.13.5.	Interaction with PPI.....	239
16.13.6.	A higher clopidogrel loading and maintenance dose?.....	240
16.14.	Prasugrel vs clopidogrel	240
16.14.1.	Comparison of efficacy.....	240
16.14.2.	The TRITON-TIMI 38 study.....	241
16.14.2.1.	Results in the overall population.....	241
16.14.2.2.	The risk of bleeding.....	243
16.14.2.3.	Analysis of stent patients.....	243
16.14.2.4.	Diabetic ACS patients.....	243
16.14.2.5.	Effects on recurrent events.....	244
16.14.3.	Prasugrel vs clopidogrel in conservative ACS therapy – The TRILOGY ACS study.....	244
16.14.4.	Pretreatment with prasugrel – The ACCOAST trial.....	245
16.15.	Ticagrelor in ACS	245
16.15.1.	The PLATO study.....	246
16.15.1.1.	The results in the overall population.....	246
16.15.1.2.	The subgroup with planned PCI.....	246
16.15.1.3.	The CABG subgroup.....	247
16.15.1.4.	Ticagrelor in diabetics.....	247
16.15.1.5.	Geographical end point differences.....	247
16.15.1.6.	CURE vs TRITON-TIMI 38 vs PLATO.....	248
16.16.	Statins in acute coronary syndrome	248
16.16.1.	The MIRACL study.....	248
16.16.2.	The A to Z study.....	250
16.16.3.	Discontinuation of statins unfavourable – Retrospective analysis of the PRISM study.....	250
16.16.4.	Statin reload before PCI – The ARMYDA-RECAPTURE study.....	250
16.17.	Invasive vs non-invasive approach in UA/NSTEMI	250
16.17.1.	The FRISC II study.....	250
16.17.2.	The TACTICS study.....	251
16.17.3.	The RITA-3 study.....	252
16.17.4.	The ICTUS study.....	252
16.18.	The importance of GP IIb/IIIa inhibitors in PCI	253
16.18.1.	The CAPTURE study.....	253
16.18.2.	The RESTORE study.....	253
16.19.	Improvement in prognosis in NSTEMI-ACS	254
16.20.	Timings during treatment of NSTEMI-ACS	254
16.20.1.	Early vs delayed PCI (TIMACS).....	254
16.20.2.	When should eptifibatide be used in NSTEMI? (EARLY ACS).....	255
16.21.	The GRACE risk score	255
16.22.	Current UA/NSTEMI guidelines	256
16.22.1.	2012 ACCF/AHA guidelines.....	256
16.22.2.	2014 AHA/ACC NSTEMI-ACS guidelines.....	257
16.22.3.	2011 ESC guidelines.....	257
16.22.4.	2013 ESC/EASD guidelines.....	258
16.22.5.	The 2015 ESC guidelines for NSTEMI-ACS.....	258

16.23.	Summary	258
16.24.	References	260
17.	The Treatment of Acute Myocardial Infarction (STEMI)	265
17.1.	The effect of thrombolysis	265
17.1.1.	The ISIS-2 study	265
17.1.2.	The GUSTO-I study	266
17.1.3.	The meta-analysis of the Fibrinolytic Therapy Trialists' Collaborative Group	266
17.1.4.	Problems of thrombolytic therapy in MI	267
17.1.5.	Is thrombolysis still relevant today?	267
17.1.5.1.	Fibrinolytics	267
17.1.5.2.	Signs of successful lysis and selection criteria	268
17.1.6.	Combination of thrombolytic agents and GP IIb/IIIa inhibitors	268
17.2.	Aspirin	268
17.2.1.	The ISIS-2 study with aspirin	268
17.2.1.1.	The meta-analysis of the Antiplatelet Trialists' Collaboration	269
17.3.	Clopidogrel	269
17.3.1.	The CLARITY-TIMI-28 study	269
17.3.2.	The COMMIT/CCS 2 study	270
17.3.3.	The ACOS Registry	270
17.3.4.	A higher loading dose of clopidogrel?	270
17.4.	Prasugrel vs clopidogrel in STEMI – The TRITON-TIMI 36 study	271
17.5.	Ticagrelor vs clopidogrel in STEMI patients – The PLATO study	271
17.6.	Anticoagulant agents	272
17.6.1.	Unfractionated heparin	272
17.6.1.1.	The meta-analysis of 21 heparin studies	272
17.6.1.2.	The ISIS-3 study	272
17.6.2.	Heparin plus rt-PA	272
17.6.3.	Low-molecular-weight heparin	273
17.6.4.	Fondaparinux	273
17.6.5.	Bivalirudin	273
17.6.5.1.	HORIZONS-AMI study	273
17.6.5.2.	The EUROMAX study	274
17.7.	Nitrates	274
17.7.1.	The meta-analysis by Yusuf	274
17.7.2.	The ISIS-4 study	275
17.7.3.	The GISSI-3 study	275
17.7.4.	The meta-analysis of the ISIS-4 study	276
17.7.5.	Indication for nitrate therapy	276
17.8.	Beta-blockers	276
17.8.1.	The MIAMI study	276
17.8.2.	The ISIS-1 study	276
17.8.3.	The meta-analysis by Yusuf	276
17.8.4.	Beta-blockers in MI in diabetics	277
17.9.	ACE inhibitors / AT ₁ receptor blockers / aldosterone-receptor blockers	277
17.9.1.	ACE-inhibitors	277
17.9.1.1.	The GISSI-3 study	277
17.9.1.2.	The ISIS-4 study	278
17.9.1.3.	The SMILE study	278
17.9.1.4.	Systematic analysis of several ACE inhibitor studies	278
17.9.2.	AT ₁ receptor blockers	278

17.9.3.	Aldosterone receptor blockers.....	278
17.10.	Calcium antagonists.....	279
17.11.	Antiarrhythmics (lidocaine prophylaxis).....	279
17.12.	PTCA in acute infarction (STEMI).....	279
17.12.1.	Immediate PTCA vs lysis with t-PA.....	279
17.12.2.	Immediate PTCA vs lysis with t-PA in GUSTO IIb.....	280
17.13.	Lysis vs transport to a PCI centre.....	280
17.13.1.	The DANAMI-2 study (lysis vs PCI).....	280
17.13.2.	Immediate PTCA vs lysis in the long term.....	280
17.13.3.	The PRAGUE-2 study.....	280
17.13.4.	PTCA vs thrombolysis in diabetics vs non-diabetics.....	281
17.14.	PTCA vs PTCA plus stent.....	281
17.15.	PCI plus stent plus GP IIb/IIIa inhibitor.....	281
17.15.1.	The ADMIRAL study.....	281
17.15.2.	The CADILLAC study.....	281
17.15.3.	Results of meta-analyses.....	282
17.15.4.	Rescue PCI / facilitated PCI.....	282
17.16.	Aim in STEMI treatment: Primary PCI.....	282
17.17.	DES vs BMS in STEMI.....	283
17.17.1.	The HORIZONS-AMI study.....	283
17.17.2.	The EXAMINATION study.....	283
17.18.	National differences in the hospitalisation time.....	283
17.19.	The prognosis in STEMI.....	283
17.20.	The new classification of infarction.....	284
17.21.	Dual antiplatelet therapy (DAPT) plus new oral anticoagulants (NOACs)?.....	284
17.21.1.	Pathophysiological background.....	284
17.21.2.	Studies on triple therapy.....	285
17.21.2.1.	The ATLAS ACS 2-TIMI 51 study.....	285
17.21.2.2.	The APPRAISE-2 study.....	285
17.21.2.3.	The RE-DEEM study.....	286
17.21.2.4.	Results of a meta-analysis.....	286
17.22.	Thrombus aspiration during STEMI.....	286
17.22.1.	The TASTE study.....	286
17.22.2.	The TOTAL study.....	286
17.23.	Intra-aortic balloon pump (IABP) counterpulsation.....	286
17.24.	Current STEMI guidelines.....	287
17.24.1.	2013 ACCF/AHA guidelines.....	287
17.24.2.	2012 ESC guidelines.....	287
17.24.3.	2013 ESC/EASD guidelines.....	288
17.24.4.	2014 ESC/EACTS guidelines.....	288
17.24.5.	Secondary prevention after STEMI.....	288
17.24.6.	2012 ESC HF guidelines.....	288
17.24.7.	ESC consensus document on the use of antithrombotic therapy in AF and ACS plus PCI.....	289
17.25.	Preventative angioplasty in STEMI?.....	289
17.26.	Summary.....	290
17.27.	References.....	291

18.	Revascularisation Procedures in Stable CAD	297
18.1.	Bypass surgery	297
18.1.1.	Venous vs arterial bypass	297
18.1.2.	CABG vs conservative therapy	297
18.1.2.1.	Results of VA, ECSS and CASS study	297
18.1.2.2.	The meta-analysis by Yusuf	298
18.1.2.3.	Depression as a prognostic indicator after CABG	298
18.1.2.4.	CABG indications in stable angina	299
18.2.	PTCA	299
18.2.1.	PTCA vs conservative therapy	299
18.2.1.1.	The RITA-2 study	299
18.2.1.2.	The meta-analysis of 6 PTCA studies	299
18.3.	Stents	300
18.3.1.	BMS stents	300
18.3.2.	Drug-eluting stents	300
18.3.3.	BMS vs DES	301
18.3.4.	Sirolimus vs paclitaxel	302
18.3.5.	Everolimus vs paclitaxel	302
18.3.6.	Biodegradable polymer drug-eluting stents	303
18.3.7.	Biodegradable stents and scaffolds	303
18.3.8.	Endothelial progenitor cell capturing stents	303
18.3.9.	The problem of re-stenosis in DES	304
18.4.	PTCA/PCI vs CABG	304
18.4.1.	The BARI study	304
18.4.2.	PCI plus stent vs bypass surgery in multivessel disease	304
18.4.3.	Meta-analyses on PCI vs CABG	305
18.4.4.	The SYNTAX study with DES	305
18.4.5.	The FREEDOM study	306
18.4.6.	Everolimus-eluting stents vs CABG in multivessel disease	307
18.5.	PTCA vs atherectomy	307
18.5.1.	The CAVEAT I study	307
18.5.2.	The BOAT study	307
18.5.3.	Venous graft stenosis	307
18.5.3.1.	The CAVEAT II study	307
18.5.3.2.	PCI in venous graft stenosis and GP IIb/IIIa receptor inhibitors	308
18.6.	Transmyocardial laser revascularisation	308
18.6.1.	The ATLANTIC study	308
18.6.2.	The PACIFIC study	308
18.6.3.	Result of a meta-analysis	308
18.7.	Beta-blockers before CABG	308
18.8.	FFR measurement	308
18.8.1.	Coronary angiography vs FFR as an additional parameter for indicating PCI – The FAME I study	308
18.8.2.	FFR vs IVUS – The FIRST study	309
18.8.3.	The significance of the FFR – The FAME I study	309
18.8.4.	Further studies on FFR	309
18.8.5.	FFR before ACB surgery?	310
18.8.6.	Non-invasive FFR measurement	310
18.9.	CABG in CAD and LVEF <35% – The STICH study	310
18.10.	Adherence to guidelines for PCI and CABG	311
18.11.	Measures in refractory angina	312

18.11.1.	Intermittent urokinase therapy	312
18.11.2.	Transmyocardial laser revascularisation	312
18.11.3.	Enhanced external counterpulsation	312
18.11.4.	Epidural spinal cord stimulation	312
18.11.5.	The coronary sinus reducer system	312
18.12.	CABG vs minimally invasive surgery	313
18.13.	The current guidelines	314
18.13.1.	2011-2014 ACCF/AHA etc. guidelines	314
18.13.2.	ESC/EACTS guidelines	314
18.13.3.	2013 ESC guidelines for stable CAD	315
18.13.4.	2013 ESC/EASD guidelines	315
18.14.	Summary	316
18.15.	References	317

19.	Stable CAD: Conservative Therapy vs Interventional/Surgical Therapy	322
19.1.	Current secondary prevention and targets in stable CAD	322
19.2.	Additive effects with four secondary prevention agents?	323
19.2.1.	Sudden cardiac death and the quality of secondary prevention	323
19.2.2.	Should all secondary prevention agents be used simultaneously?	324
19.2.3.	Quality of secondary prevention after acute coronary syndrome and mortality	324
19.2.4.	Consistent control of all lipid fractions	325
19.2.5.	Quality of current secondary prevention	325
19.3.	Individual conservative measures in chronic stable CAD vs PCI	326
19.3.1.	Physical exercise vs PCI with stent activity	326
19.3.2.	Statin vs stent – The AVERT study	326
19.4.	Optimised secondary prevention vs PCI with stent	327
19.4.1.	PCI in chronic stable CAD and optimised secondary prevention – The COURAGE study	327
19.4.2.	Quality of life in the COURAGE study	328
19.4.3.	Comparison of the BEAUTUL substudy with COURAGE	328
19.5.	Is late reperfusion worthwhile? The open artery hypothesis	329
19.6.	Intensive medical therapy vs prompt revascularisation in diabetics with stable CAD	330
19.6.1.	The BARI 2D study	330
19.6.2.	hsTNT and cardiac events in the BARI 2D study	330
19.7.	Meta-analyses on optimised secondary prevention vs PCI	331
19.7.1.	Result of a meta-analysis (11 studies)	331
19.7.2.	Results of three meta-analyses	331
19.7.3.	Drug vs different interventional therapies	332
19.7.4.	Relief of angina: drug therapy vs PCI – A meta-analysis	332
19.8.	FFR and OMT vs OMT – The FAME II study	333
19.8.1.	First analysis after seven months	333
19.8.2.	The two-year data of FAME II	334
19.9.	Routine vs quantitative coronary angiography	335
19.10.	No successes with low risk	335
19.10.1.	Beta-blockers in the presence of a low heart rate	335
19.10.2.	Ivabradine in stable CAD	335
19.10.2.1.	Ivabradine in the BEAUTUL study	335
19.10.2.2.	The SIGNIFY study in preserved LVF	336
19.10.3.	Omega-3 fatty acids	336
19.11.	Conservative vs interventional/surgical therapy	337

19.12.	The problem and a suggested solution	337
19.13.	COURAGE and Wall Street – A controversial subject	337
19.13.1.	Controversies on Investigations	337
19.13.1.1.	Stress ECG	337
19.13.1.2.	Functional investigations	338
19.13.1.3.	Call for additional physiological parameters	338
19.13.1.4.	Coronary angiography done too often	338
19.13.1.5.	Regional differences in PCI frequency	339
19.13.1.6.	Periprocedural myocardial infarctions	340
19.13.2.	Controversies regarding treatment	340
19.13.3.	OMT in stable angina	340
19.14.	Prioritising before rationing	341
19.15.	Guidelines for chronic stable CAD	341
19.15.1.	ACCF/AHA etc. guidelines	341
19.15.2.	2013 ESC and ESC/EASD guidelines for stable CAD	341
19.15.3.	2014 ESC/EACTS guidelines for myocardial revascularisation	341
19.16.	Summary	342
19.17.	References	343
20.	Therapy in Postinfarction Failure	347
20.1.	Pathophysiological background	347
20.2.	Spironolactone in NYHA class III and IV	347
20.3.	Eplerenone in NYHA II – The EMPHASIS-HF study	347
20.4.	Eplerenone after acute myocardial infarction with LV dysfunction	348
20.4.1.	The EPHEsus study	348
20.4.2.	Aldosterone antagonists and acute cardiac death	349
20.5.	Eplerenone in acute STEMI without heart failure?	349
20.6.	Stem cells in chronic ischaemic cardiomyopathy	350
20.7.	Beta-blockers in heart failure and AF	350
20.8.	The STITCH substudy on surgical ventricle reconstruction	350
20.9.	A new strategy: Angiotensin receptor neprilysin inhibitor (ARNI)	350
20.9.1.	Mode of action	350
20.9.2.	The PARADIGM-HF study	351
20.10.	Guidelines	352
20.10.1.	Overview of guidelines on indications for aldosterone antagonists	352
20.10.2.	2011 and 2012 ESC guidelines	353
20.10.3.	2013 ESC/EASD guidelines	353
20.10.4.	2013 ACCF/AHA guidelines	353
20.10.5.	Oral anticoagulants?	354
20.11.	Summary	354
20.12.	References	355
21.	Antiarrhythmic Drugs	357
21.1.	Pathophysiological background	357
21.2.	The pro-arrhythmogenic effect in relation to the ejection fraction	357
21.3.	Clinical studies in ventricular extrasystoles	357
21.3.1.	The CAST studies	357
21.4.	Amlodarone in heart failure	358
21.4.1.	The CHF-STAT study with amlodarone	358

23.2.7.	Visceral obesity	396
23.2.8.	Procedure in diabetes mellitus.....	397
23.2.8.1.	Weight loss in type 2 diabetes – The Look AHEAD study	397
23.2.8.2.	The effect of SGLT2 inhibitors in the EMPA-REG Outcome study.....	397
23.2.8.3.	Effects of the GLP-1 analogue liraglutid	398
23.3.	Smoking	398
23.3.1.	Smoking as a risk factor	398
23.3.2.	Cessation of smoking after PTCA.....	400
23.3.3.	Cessation of smoking in CABG surgery.....	400
23.3.4.	Smoking quantity	400
23.3.5.	Benefit of stopping smoking.....	400
23.4.	Alcohol	401
23.4.1.	Amount of alcohol, risk and benefit.....	401
23.4.2.	Wine as a protective agent?	401
23.4.3.	Alcohol in post-MI patients – The Physicians' Health Study	402
23.4.4.	Further studies on alcohol.....	402
23.4.5.	Position of the ACCF/AHA et al.....	403
23.4.6.	Alcohol and exercise	403
23.4.7.	Alcohol and diabetes.....	403
23.4.8.	Perception of the protective effects of red wine	404
23.5.	Physical activity and rehabilitation	404
23.5.1.	Physical activity	404
23.5.2.	Rehabilitation.....	405
23.5.2.1.	AHA guidelines on rehabilitation	406
23.5.2.2.	Rehabilitation in older CAD patients	406
23.6.	When should lifestyle changes begin?	406
23.7.	Sex hormones (oestrogens/testosterone) in prevention?	407
23.8.	Multivitamins and minerals?	407
23.9.	Dark chocolate	407
23.10.	Guidelines on lifestyle	408
23.10.1.	2013 ESC guidelines for lifestyle in stable CAD	408
23.10.2.	2013 ESC/EASD guidelines	408
23.10.3.	2013 AHA/ACC guidelines for lifestyle (primary and secondary prevention).....	408
23.10.4.	2013 AHA/ACC/TOS guidelines on overweight/obesity	408
23.11.	Summary	408
23.12.	References	410

24.	Abbreviations	415
------------	----------------------	------------

	Index	418
--	--------------	------------